Filing Flows › RenovoRx (RNXT) › Q2 2026 › vs Q1 2026
RenovoRx (RNXT) Q2 2026 vs Q1 2026 (quarter over quarter)
RenovoRx's revenue rose $346K (+61%) from $563K in Q1 2026 to $909K in Q2 2026.
RenovoRx, Q2 2026: revenue $909K (+115% year over year), operating margin -368.4%, net loss $2.9M, operating cash flow −$2.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $909K | $563K | $346K | +61% |
| Other income, net | $438K | −$52K | $490K | — |
| Net loss | $2.9M | $3.5M | −$610K | -17% |
| Costs & expenses | $4.3M | $4.1M | $174K | +4% |
| Operating costs | $4.3M | $4.0M | $226K | +6% |
| Cost of revenue | $143K | $84K | $59K | +70% |
| Research & development | $1.2M | $1.2M | −$28K | -2% |
| SG&A | $2.9M | $2.7M | $195K | +7% |
| Operating cash sources | $3.4M | $4.0M | −$585K | -15% |
| Depreciation | $5K | $1K | $4K | +400% |
| Share-based compensation | $570K | $317K | $253K | +80% |
| Cash used in operations | $2.9M | $3.7M | −$842K | -23% |
| Net loss absorbed | $2.9M | $3.5M | −$610K | -17% |
| Working capital & other | $531K | $506K | $25K | +5% |
Questions
How much did RenovoRx's revenue grow quarter over quarter in Q2 2026?
RenovoRx's revenue rose $346K (+61%) from $563K in Q1 2026 to $909K in Q2 2026.